| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.024 | 0.9 |